People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced ... DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked to a reduced ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

ZURICH and NESS ZIONA, Israel - NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced plans for a merger, aiming to enhance diabetes treatment by combining their expertise ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...